Vanessa Estall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vanessa Estall has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Angela Webb
Peter MacCallum Cancer Centre Melbourne Victoria Australia
2 shared publications - Mathias Bressel
Sir Peter MacCallum Department of Oncology University of Melbourne Parkville Australia
2 shared publications - Albert Tiong
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
1 shared publication Angela Allen
Waikato Regional Cancer Centre Hamilton New Zealand
1 shared publicationChris McCormack
Peter MacCallum Cancer Centre Melbourne Victoria Australia
1 shared publication- Danny Rischin
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
1 shared publication
Latest Publications
- Open Access
- 9 November 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 63 (1) , 43-52
Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors
Purpose: This study examined the clinical outcomes and prognostic factors of patients with metastatic cutaneous SCC metastatic to the axilla and groin when managed with curative‐intent lymphadenectomy and received (neo)adjuvant treatment.Methods and Materials: We conducted a single institution retrospective review. Patients who had nodal disease without distant spread were 18 years or older with no non‐cutaneous primary identified.Results: From January 2000 to July 2015, 78 patients were treated for axilla (64, 82%) or inguinal (14, 18%) involvement with cSCC. The median age was 75.5 years (range: 29–95), and 8 patients (11%) were immunosuppressed. The median size of the largest node was 45 mm (range: 8–135), and extracapsular extension was found in 63 (81%) cases. A majority of patients were treated with surgery alone (21, 26.9%) and surgery with adjuvant radiation therapy (54, 69%). The 2‐year OS and PFS were 50% (95% CI: 40%–63%) and 43% (95% CI: 33%–56%), and 5‐year OS and PFS were 33% (95% CI:23%–47%) and 32% (95% CI:22%–46%) respectively in the entire cohort. On univariable analysis, factors associated with longer OS were as follows: younger age (HR 1.1, 95% CI: 0.9–1.3 P = 0.021), improved performance status (HR 1.5, 95% CI:1.0–2.3 P = 0.026), lack of immunosuppression (HR 3.3, 95% CI: 1.5–7.3 P = 0.001), lower lymph node ratio (HR 1.2, 95% CI:1.0–1.3 P = 0.007), lower number of positive nodes (HR 1.1, 95% CI:1.0–1.2 P = 0.004) and the use of radiation therapy (HR 0.5, 95% CI:0.3–0.9 P = 0.012).Conclusion: Metastasis to the axilla and groin with cSCC has poor outcomes with standard treatment. The addition of immunotherapy warrants investigation.
- 9 November 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 63 (1) , 43-52
Open AccessCutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors
Purpose: This study examined the clinical outcomes and prognostic factors of patients with metastatic cutaneous SCC metastatic to the axilla and groin when managed with curative‐intent lymphadenectomy and received (neo)adjuvant treatment.Methods and Materials: We conducted a single institution retrospective review. Patients who had nodal disease without distant spread were 18 years or older with no non‐cutaneous primary identified.Results: From January 2000 to July 2015, 78 patients were treated for axilla (64, 82%) or inguinal (14, 18%) involvement with cSCC. The median age was 75.5 years (range: 29–95), and 8 patients (11%) were immunosuppressed. The median size of the largest node was 45 mm (range: 8–135), and extracapsular extension was found in 63 (81%) cases. A majority of patients were treated with surgery alone (21, 26.9%) and surgery with adjuvant radiation therapy (54, 69%). The 2‐year OS and PFS were 50% (95% CI: 40%–63%) and 43% (95% CI: 33%–56%), and 5‐year OS and PFS were 33% (95% CI:23%–47%) and 32% (95% CI:22%–46%) respectively in the entire cohort. On univariable analysis, factors associated with longer OS were as follows: younger age (HR 1.1, 95% CI: 0.9–1.3 P = 0.021), improved performance status (HR 1.5, 95% CI:1.0–2.3 P = 0.026), lack of immunosuppression (HR 3.3, 95% CI: 1.5–7.3 P = 0.001), lower lymph node ratio (HR 1.2, 95% CI:1.0–1.3 P = 0.007), lower number of positive nodes (HR 1.1, 95% CI:1.0–1.2 P = 0.004) and the use of radiation therapy (HR 0.5, 95% CI:0.3–0.9 P = 0.012).Conclusion: Metastasis to the axilla and groin with cSCC has poor outcomes with standard treatment. The addition of immunotherapy warrants investigation.
- Open Access
- 10 June 2016
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 58 (4) , e207-e215
Outcomes following management of squamous cell carcinoma of the scalp: A retrospective series of 235 patients treated at the Peter MacCallum Cancer Centre
Background: Squamous cell carcinoma of the scalp is a common clinical problem in an aging population. Despite its high incidence, little has been documented regarding treatment or outcomes.Methods: We retrospectively analysed 235 cases treated with curative intent at Peter MaCallum Cancer Centre between 1998 and 2010. The cohort was analysed for its characteristics, management, survival and prognostic factors.Results: The patients were primarily male (88%) with a median age of 79 years (range 53–98 years). There was a high proportion of immunosuppressed patients (29%) and stage T2 (48%) tumours. Management included surgery (45%), radiotherapy (28%) and surgery and adjuvant radiotherapy (26%). Median follow up from treatment was 4.5 years. Estimated 5‐year overall survival (OS), disease‐specific survival and progression‐free survival (PFS) were 59, 94 and 51%, respectively. The 5‐year cumulative incidence of local and regional relapse was 11 and 7%, respectively. There were four patients who developed distant metastases and died of their disease. Statistically significant prognostic factors identified for poor outcomes for OS and PFS were T2 stage (hazard ratio [1.7 and 2.1) and immunosuppression (HR 3.3 and 3.4).Conclusions: We conclude the presence of immunosuppression and T2 stage is prognostic for survival. Further research to establish treatment principles is warranted.
- 10 June 2016
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 58 (4) , e207-e215
Open AccessOutcomes following management of squamous cell carcinoma of the scalp: A retrospective series of 235 patients treated at the Peter MacCallum Cancer Centre
Background: Squamous cell carcinoma of the scalp is a common clinical problem in an aging population. Despite its high incidence, little has been documented regarding treatment or outcomes.Methods: We retrospectively analysed 235 cases treated with curative intent at Peter MaCallum Cancer Centre between 1998 and 2010. The cohort was analysed for its characteristics, management, survival and prognostic factors.Results: The patients were primarily male (88%) with a median age of 79 years (range 53–98 years). There was a high proportion of immunosuppressed patients (29%) and stage T2 (48%) tumours. Management included surgery (45%), radiotherapy (28%) and surgery and adjuvant radiotherapy (26%). Median follow up from treatment was 4.5 years. Estimated 5‐year overall survival (OS), disease‐specific survival and progression‐free survival (PFS) were 59, 94 and 51%, respectively. The 5‐year cumulative incidence of local and regional relapse was 11 and 7%, respectively. There were four patients who developed distant metastases and died of their disease. Statistically significant prognostic factors identified for poor outcomes for OS and PFS were T2 stage (hazard ratio [1.7 and 2.1) and immunosuppression (HR 3.3 and 3.4).Conclusions: We conclude the presence of immunosuppression and T2 stage is prognostic for survival. Further research to establish treatment principles is warranted.